API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/12/27/2801324/35409/en/Cytokinetics-Announces-Positive-Results-From-SEQUOIA-HCM-the-Pivotal-Phase-3-Clinical-Trial-of-Aficamten-in-Patients-With-Obstructive-Hypertrophic-Cardiomyopathy.html
https://www.globenewswire.com//news-release/2023/09/06/2738264/35409/en/Cytokinetics-Announces-Start-of-ACACIA-HCM-a-Pivotal-Phase-3-Clinical-Trial-of-Aficamten-in-Patients-With-Symptomatic-Non-Obstructive-Hypertrophic-Cardiomyopathy.html
https://seekingalpha.com/article/4616160-aficamten-sets-cytokinetics-apart-in-cardiomyopathy
https://www.globenewswire.com/news-release/2022/02/23/2390249/35409/en/Cytokinetics-Announces-Start-of-SEQUOIA-HCM-a-Phase-3-Clinical-Trial-of-Aficamten-in-Patients-With-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy.html
https://endpts.com/cytokinetics-gets-the-royalty-treatment-snagging-up-to-450m-to-support-closely-watched-heart-programs/